Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke

NCT06202378 is registered in ClinicalTrials.gov with Shanghai Hutchison Pharmaceuticals Limited as lead sponsor.

NCT NCT06202378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06202378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Placebo Controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of SHPL-49 Injection in the Treatment of Acute Ischemic Stroke
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited
Phase
Phase 2
Overall status
Completed
Start date
December 29, 2023
Completion date
December 16, 2024
Enrollment
270 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke